secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0001356576-25-000038
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035
--------------------------------------------------------------------------------

- Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.
- Six Orange Book patents listed; three expire Sept 2029, two Feb 2033, one April 2035.
- Company intends to vigorously enforce its Qelbree intellectual property rights.
- Currently reviewing details of the ANDA filings from third parties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000038/0001356576-25-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657625000038/supn-20250522.htm
  HTML page:      https://secwatch.observer/filing/0001356576-25-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer